ID 11046
Alternative Names: ID-11046Latest Information Update: 28 Feb 2025
At a glance
- Originator Ildong Pharmaceutical
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for research development in Pain in South Korea
- 25 Jan 2021 ID 11046 is available for licensing as of 25 Jan 2021. https://www.ildong.com/
- 25 Jan 2021 Early research in Pain in South Korea (Ildong Pharmaceutical pipeline, January 2021)